Skip to main content

Advertisement

Table 5 Melanomas with coexisting mutations in 31 melanomasa

From: Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing

  BRAF HRAS KRAS NRAS PIK3CA KIT CM (%)b
BRAF 1c 3 1 4 5 5 18 (10%)
HRAS 3 0 1 0 1 1 6 (67%)
KRAS 1 1 0 1 0 0 3 (25%)
NRAS 4 0 1 2d 2 1 9 (8.1%)
PIK3CA 5 1 0 2 1 1 9 (75%)
KIT 5 1 0 1 1 2e 8 (36%)
  1. aIncluding 29 tumors with 2 mutations and 2 tumors with 3 mutations
  2. bCoexisting mutation (CM) within different genes
  3. cp.S605I with unknown kinase activity and p.V600E within the same allele
  4. dOne with NRAS p.Q61L and p.Y64D of unknown activating status, and one with NRAS p.G13D, p.Q61K and PIK3CA p.E542G
  5. eOne with p.V560A and p.N822Y, and one with p.P573S, p.F681I and p.N822I